Indmedica Home | About Indmedica | Medical Jobs | Advertise On Indmedica
Search Indmedica Web
Indmedica - India's premier medical portal

Biomedical Research

Oxidative stress, serum homocysteine and serum nitric oxide in different stages of chronic renal failure

Author(s): Nitin S. Nagane, Jayshree V. Ganu, Rajeev Gandhi

Vol. 20, No. 1 (2009-01 - 2009-04)

Biomedical Research 2009; 20 (1): 71-74

Nitin S. Nagane(1), Jayshree V. Ganu(2), Rajeev Gandhi(3)

1 – Department of Biochemistry, Bharti Vadyapeeth University Medical College and Hospital, Sangli (Maharashtra), India
2 – Department of Biochemistry, Government Medical College, Miraj, Sangli, (Maharashtra), India
3 – Department of Nephrology, Wanless Hospital, Miraj, Sangli, Maharahtra, India


Chronic renal failure is accompanied by oxidative stress, which is caused by reactive oxygen species and impaired antioxidant defense. In this study we investigated oxidative stress in chronic renal failure patients.

In the present study, 150 CRF patients and 50 healthy controls matching age and sex were included. We have estimated serum lipid peroxidation, serum superoxide dismutase, serum nitric oxide and serum homocysteine in different stages of CRF and healthy individuals. After 12 hours overnight fasting blood samples were collected taking aseptic precautions in plain bulbs. The statistical method used to compare the data was ‘Z’ test.

The results show that the mean levels of serum lipid peroxidation and serum homocysteine was elevated (P<0.001, P>0.05) elevated in different stages of CRF as compared to that of controls. The activity of serum superoxide dismutase and nitric oxide were reduced (P<0.001, P>0.05) in CRF as compared to that of controls. These parameters may be important with respect to the high morbidity and mortality of cardiovascular disorder found in patients with chronic renal failure.

Key words: Chronic renal failure (CRF), Superoxide dismutase (SOD), Lipid peroxidation (LPO), Nitric Oxide (NO٭), Oxygen free radical (OFR)

Accepted January 26 2009


Reactive oxygen species (ROS) are intermediary metabolites that are normally produced in the course of oxygen metabolism [1]. Oxidative stress defines an imbalance between formation of ROS and antioxidative defence mechanism. In view of the profound biological effects of ROS, in recent years numerous clinical and experimental studies focused on detection of signs of oxidative stress in renal failure patients [2].

It is accepted that patients with advanced CRF have greater risk for the development of atherosclerosis and associated morbidity and mortality [3]). In addition, recent evidence suggest that this process of cardiovascular damage start very early during progression in well-defined CRF, long before end-stage renal disease is developed [1]. In this context, we thought it worthwhile to study the potential role of oxidative stress in the pathogenesis of atherosclerosis and other alterations in CRF

Hyperhomocysteinemia was first related to renal failure in 1997 by Cohen et al. [5]. As with other amino acids, the healthy kidney has a high capability to filter, reabsorb and metabolize homocysteine. In addition to the filtered load, homocysteine uptake may also occur on the basolateral tubular cell surface, which means that kidneys play a primordial role in homocystine handling. Uremic patients have high mortality rate of 9% per year attributable mainly to cardiovascular disease, which is 30 times the risk in the general population [6]). This risk cannot be explained only by the conventional cardiovascular risk factors. Hyperhomocysteinemia may be one of the risk factors in chronic renal diseases.

With a view of understanding the potential role of oxidative stress in the pathogenesis of atherosclerosis and other alterations in CKD, the present study was undertaken. We planned to determine the levels of homocysteine the risk factor for cardiovascular events, the levels of lipid peroxidation as a marker of oxidative stress and the activity of SOD, the antioxidant enzyme required for scavenging the OFR and nitric oxide the parameter concerned with endothelial function in chronic renal failure patients.

Material and Method

In the present study, 150 CRF patients and 50 healthy controls matching in age and sex were included. The patients were attending OPD or admitted in nephrology ward and renal intensive care unit of Wanless Hospital Miraj, Bharti Vidyapeeth University Medical College, Hospital Sangli and Government Medical College and Hospital Miraj. The patients were selected on the basis of their estimated glomerular filtration rate (eGFR). According to National Kidney Foundation guidelines, the stages of CRF varied between 1 to 5 depending on eGFR [7] and eGFR was determined by using MDRD equation displayed on Table 1.

Table I: Classification of CRF Patients according to eGFR

1 90+ Normal Kidney function but abnormalities in urine sample
2 60-89 Mildly reduced kidney function
3 30-59 Moderately reduced kidney function
4 15-29 Severely reduced kidney function
5 14 or less Very sever or End Stage Renal Disease (ESRD)
Controls 120-125 Normal kidney function

Upon inclusion of the patients, a record was made of all current medications being taken, risk factor for cardiovascular disease, current and historic relevant data by means of a written evolution and the database of clinical history was updated. The patients who are willing to participate with informed concent were included in the present study. Terminally ill patients, non cooperative, non willing patients and patients with multiorgan involvement were excluded in this study.

8-10 ml of blood from each patient was collected in plain bulbs taking aseptic precautions. Separated sera were processed for the assay of biochemical analytes. Lipid Peroxidation was measured as MDA in serum by the method of Kei Satoh [8]). The colour produced by the reaction of thiobarbituric acid with MDA was measured at 530 nm with the help of spectrophotometer. The results were expressed as nmol/ml. Superoxide Dismutase was assayed by the method of Marklund and Marklund [9] modified by Nischal HK [10]. This method is based on the ability of superoxide dismutase to inhibit autoxidation of pyrogallol under specific conditions. Spectrophotometric readings were taken at 420 nm and expressed as units/ml. Nitric Oxide was assayed by the method of Najwa K.Cortas and Nabil W. Wakid by cadmium reduction method and colour complex produced was measured at 540nm [11]. Homocysteine was assayed by chemiluminescence and results expressed as Ámol/l [12].

The statistical analysis included ‘Z’ test and regression analysis for correlation coefficient. Results

Table II shows the mean values of different biochemical analytes in different stages of CRF patients.

There was a slight and insignificant increase in the mean value of serum lipid peroxidation in the stage 1st patients (P>0.05) of CRF, as compared to controls. Further, significant and progressive rise was observed in the mean value of serum lipid peroxidation from stage 2nd to stage 5th in CRF patients (P<0.001) when compared to controls.

There was no significant change in the mean values of serum SOD and nitric oxide in stage 1st and 2nd in CRF patients (P>0.05) as compared to controls, but significant and progressive decline was observed in the mean values of serum SOD and nitric oxide from stage 3rd, 4th and 5th in CRF patients (P<0.001) as compared to controls.

Mean values of serum homocysteine in stage 1st of CRF patients was slightly increased and the increase was insignificant (P>0.05) as compared to controls. While significant and progressive rise was observed from stage 3rd to 5th in CRF patients as compared to controls.

In the present study significant correlation for lipid peroxidation with serum SOD, serum nitric oxide and serum homocysteine were observed in CRF patients. Whereas serum LPO levels show negative correlation with serum SOD (r = -0.6979) and nitric oxide levels (r = -0.60766), serum LPO levels have positive correlation with serum homocysteine levels (r = 0.71265).

Table II: The mean values of different biochemical analytes in different stages of CRF patients.

of CRF
No. Lipid Peroxidation
Superoxide Dismutase
U/mL of Hb
Nitiric oxide
1 30 2.82±0.42٭ 4.70±1.14٭ 55.63±3.03٭ 8.40±2.73٭
2 30 2.91±0.34٭٭ 4.47±1.28٭ 54.1±3.46٭ 9.48 ±2.30٭٭
3 30 4.46±0.58٭٭٭ 3.42±0.85٭٭٭ 51.94±4.02 ٭٭ 12.95±2.78٭٭٭
4 30 5.15±0.73٭٭٭ 2.35±0.51٭٭٭ 49.9±3.58٭٭٭ 15.74±3.03٭٭٭
5 30 7.25±0.69٭٭٭ 1.78±0.51٭٭٭ 46.83±3.16٭٭٭ 17.45±3.23٭٭٭
Control 50 2.67±0.50 4.98 ± 1.15 55.63±3.033 7.83±2.84

٭P> 0.05 Not significant
٭٭P< 0.05 - significant
٭٭٭P < 0.001 - highly significant


The oxidative-antioxidative system imbalance leads to the pathology called oxidative stress [13]. Oxidative stress occurs when there is an excessive free radical production and/or low antioxidant defence and results in chemical alterations of biomolecules, which cause structural and fuctional modifications. Polyunsaturated fatty acids are oxidized in vivo by free radicals and other reactive species, subsequent degradation of oxidized lipid molecules leads to the formation of several specific metabolites that include aldehydes of variable chain length, such as malondialdehyde (14) .In our study the mean level of Lipid peroxidation are significantly increased from stage 2nd to 5th in CRF patients. Oxidative stress may play a role in the progression of chronic renal failure (CRF) and in the genesis of atherosclerosis.

Renal sources for ROS are activated macrophages, vascular cells and various glomerular cells. In CRF patients consequences may be aggravated by the concomitant lowering of the patients defence system. The balance between formation of ROS and antioxidative defence mechanisms depends on the activity of enzymes such as superoxide dismutase [14-16]. In our study the stagewise mean activity of superoxide dismutase was significantly reduced from stage 3rd to 5th in CRF patients. Oxidative stress may lead to impaired activities of endogenous enzymatic free radical scavengers like SOD.

Nitric oxide (NO) is one of the main factors involved in the antiatherosclerotic effects of endothelium. In our study the mean serum level of Nitric oxide is significantly reduced stagewise from stage 2nd to 5th in CRF patients. We found elevated concentration of serum LPO, which is the marker of enhanced concentration of oxygen radical species that can inactivate nitric oxide in CRF .This is supported by negative correlation found by us, between serum LPP and serum nitric oxide levels in CRF patients. Due to reduced serum SOD activity, the superoxide ion can rapidly react with nitric oxide to form peroxynitrite, a compound with diminished vasodilatory properties [17-18]. Impaired endothelial dependent vasodilatation was also observed in other studies in patients with renal insufficiency [18]).

Another cardiovascular disease (CVD) risk factor is homocysteine [21]. It was also found to be significantly increased in a progressive manner for stage 2nd to 5th in CRF. We also found a positive correlation between seum homocysteine and serum LPO levels. Endothelium dysfunction and oxidative stress may be responsible for a metabolic block distally in transsulfuration route or at the homocysteine remethylation site causing hyperhomocysteinemia [19-20]. Hyperhomocysteinemia, oxidative stress and endothelial dysfunction may be interrelated, forming a cascade of atherothrombotic processes in CRF.

The present findings allow us to conclude that patients with CRF have reduced activity of SOD, increased level of oxidative stress markers along with homocysteine which can lead to endothelial cell dysfunction and reduction in nitric oxide levels. These factors may be important with respect to the high morbidity and mortality of CVD found in patients with CRF. These parameters can predict severity of CVD associated with CRF and can be used for better control of progression of stages of CRF. As oxidative stress and inflammation appear to be important in the pathogenesis of CVD in CRF patients, antioxidant treatment strategies could be beneficial. Classification of CRF on the basis of eGFR is important. If CRF patients are classified according to eGFR and biochemical parameters like SOD, LPO, NO٭ and homocysteine are measured, it will help the clinician to achieve better management.


  1. Zalba G, Fortuno A, Diez J. Oxidative stress and atherosclerosis in early chronic disease. Nephrology Dialysis Transplantation 2006; 21(10): 2686-2690.
  2. Galle J. Oxidative stress in chronic renal failure. Nephrol Dial Transplant 2001; 16: 2135-2137.
  3. Sarnak MJ, Levey AS, Schoolwerth AC. Kidney disease as a risk factor for development cardiovascular disease. A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 2003; 42: 1050-1065.
  4. Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 2004; 24: 469-473.
  5. Cohen BD, Patel H, Kornhauser RS. Alternate reasons for atherogenesis in uremia. Proc Clin Dial Transplant Forum 1997; 7: 178-180.
  6. Mallat SG, Aoun M. Hyperhomocysteinemia and its role in chronic renal failure. Soudi Journal of Kidney Diseases and Transplantation 2002; 13(3): 336-343.
  7. National Kidney foundation. K/DOQI clinical practice guidelines for chronic kidney disease evalution, classification, and stratification. Am J Dis 2002; 39: 1-266.
  8. Satoh K. Plasma lipid peroxide in cerebrovascular disorder determined by a new colorimetric method. Clinica Chimica Acta 1978; 90: 37-43.
  9. Marklund S, Marklund G. Involovement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974; 47: 469-474.
  10. Nischal HK, Sharma MP, Goyal RK, Kaushik GG. Serum superoxide dismutase levels in diabetes mellitus with or without microangiopathic complications.JAPI 1998; 46(10): 853-855.
  11. Cortas NK, Wakid NW. Determination of inorganic nitrate in serum and urine by a kinetic cadmimum method. Clin Chem 1990; 36(8):1440-1443.
  12. Estimation of Homocysteine by automated chemiluminescence’s Bayer Health care (Company system manual).
  13. Mastalerz-Migas A, Steciwka A, Pokorski M, Pirogowicz I, Drobnik J, Bunio A, Muszynska A, Jasinska A. What influences the level of oxidative stress as measured by 8-Hydroxy-2’-Deoxyguanosine in patients on hemodialysis? Jounal of physiology and pharmacology 2006; 4: 199-205.
  14. Menevse E, Siverikaya A, Karagozoglu E, Tiftik AM, Turk S. Study of elements, antioxidants and lipid peroxidation in hemodialysis patients. Turk J Med Sci 2006; 36(5): 279-284.
  15. Dakshinamurthy KV, Srinivasa Rao PVLN, Saibaba KSS, Sheela RB, Venkataramana G, Shyam C, Sreekrishna V. Antioxidant status in patients on maintenance hemodialysis. Indian J Nephrol 2002; 12: 77-80.
  16. Luciak M. Antioxidants in the treatment of patients with renal failure. Annales Academiae Medicae Bialostocensis 2004; 49: 157-161.
  17. Wever R, Boer P, Hijmering M, Stroes E, Verhaar M, Kastelein J, Versluis K, Lagerwerf F, Rijn VH, Koomans H, Rabelink T. Nitric oxide production is reduced in patients with chronic renal failure 1999; 19: 1168-1172
  18. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 2001; 12: 2747-2752.
  19. Guldener CV. Why homocysteine elevated in renal failure and what is can be expected from homocysteine lowering? Nephrology Dialysis Transplantation 2006; 21: 1161-1166.
  20. Guldener CV. Homocysteine and the kidney. Current Drug Metabolism 2005; 6: 23-26.
  21. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L, Rosenberg IH. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients a prospective study. Arteriosclerosis, Thrombosis, and Vascular Biology 1997; 17: 2554-2558.


Nitin S. Nagane
Department of Biochemistry, Bharti Vadyapeeth University Medical College and Hospital,
Sangli 416416. (Maharashtra) India

Phone: +98907346

Access free medical resources from Wiley-Blackwell now!

About Indmedica - Conditions of Usage - Advertise On Indmedica - Contact Us

Copyright © 2005 Indmedica